Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment

International Journal of Hematology

Volumn 92, Issue 4, 2010, Pages 664-666

  Minami, Yosuke ^a   Kajiguchi, Tomohiro ^b   Abe, Akihiro ^a   Ohno, Toshihito ^b   Kiyoi, Hitoshi ^c   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOSEI GENERAL HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib; T315I

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; COMPLEMENTARY DNA; IMATINIB;

ADULT; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER DIAGNOSIS; CANCER RESISTANCE; CASE REPORT; CELL POPULATION; CELLULAR DISTRIBUTION; CHROMOSOME ABERRATION; CHROMOSOME G BAND; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; COMPLETE HEMATOLOGIC RESPONSE; DNA SEQUENCE; DRUG DOSE ESCALATION; EARLY DIAGNOSIS; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MEGAKARYOCYTE ERYTHROID PROGENITOR; MONONUCLEAR CELL; MYELOID PROGENITOR CELL; PARTIAL CYTOGENETIC RESPONSE; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN SIZE; STEM CELL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENES, ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RETROSPECTIVE STUDIES;

EID: 78549282051     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0706-6     Document Type: Article

References (11)

1. FE Nicolini MJ Mauro G Martinelli DW Kim S Soverini MC Muller, et al. 2009 Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation Blood 114 5271 5278 1:CAS:528:DC%2BC3cXislWkug%3D%3D 10.1182/blood-2009-04-219410 19843886
2. A Quintas-Cardama H Kantarjian J Cortes 2009 Imatinib and beyond-exploring the full potential of targeted therapy for CML Nat Rev Clin Oncol 6 535 543 1:CAS:528:DC%2BD1MXhtVKjsrjP 10.1038/nrclinonc.2009.112 19652654
3. S Branford JV Melo TP Hughes 2009 Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114 5426 5435 1:CAS:528:DC%2BC3cXhtFaquw%3D%3D 10.1182/blood-2009-08-215939 19880502
4. CH Jamieson LE Ailles SJ Dylla M Muijtjens C Jones JL Zehnder, et al. 2004 Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML N Engl J Med 351 657 667 1:CAS:528:DC%2BD2cXms1Oktbg%3D 10.1056/NEJMoa040258 15306667 (Pubitemid 39063268)
5. A Abe Y Minami F Hayakawa K Kitamura Y Nomura M Murata, et al. 2008 Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy Int J Hematol 88 471 475 1:CAS:528:DC%2BD1MXkvVamtw%3D%3D 10.1007/s12185-008-0221-1 19039626
6. M Baccarani J Cortes F Pane D Niederwieser G Saglio J Apperley, et al. 2009 Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 6041 6051 1:CAS:528:DC%2BC3cXhtVWisLY%3D 10.1200/JCO.2009.25.0779 19884523
7. X Jiang KM Saw A Eaves C Eaves 2007 Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells J Natl Cancer Inst 99 680 693 1:CAS:528:DC%2BD2sXmsFarsrg%3D 10.1093/jnci/djk150 17470736 (Pubitemid 47073530)
8. C Roche-Lestienne JL Laï S Darré T Facon C Preudhomme 2003 A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia N Engl J Med 348 2265 2266 10.1056/NEJMc035089 12773665 (Pubitemid 36618149)
9. T Lange B Park SG Willis MW Deininger 2005 BCR-ABL kinase mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 4 1761 1766 1:CAS:528:DC%2BD28XktVChu7Y%3D 16319529
10. DW Sherbenou MJ Wong A Humayun LS McGreevey P Harrell R Yang, et al. 2007 Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib Leukemia 21 489 493 1:CAS:528:DC%2BD2sXhvFWktrY%3D 10.1038/sj.leu.2404554 17252009
11. F Michor 2008 Mathematical models of cancer stem cells J Clin Oncol 26 2854 2861 10.1200/JCO.2007.15.2421 18539964